Compare ELUT & CASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELUT | CASI |
|---|---|---|
| Founded | 2015 | 1991 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.3M | 24.9M |
| IPO Year | 2020 | 1996 |
| Metric | ELUT | CASI |
|---|---|---|
| Price | $0.59 | $0.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $7.00 | $4.00 |
| AVG Volume (30 Days) | ★ 502.1K | 35.3K |
| Earning Date | 11-06-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $21,746,000.00 | ★ $26,846,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.08 | 21.72 |
| 52 Week Low | $0.50 | $0.75 |
| 52 Week High | $3.99 | $3.29 |
| Indicator | ELUT | CASI |
|---|---|---|
| Relative Strength Index (RSI) | 43.34 | 30.97 |
| Support Level | $0.52 | $0.83 |
| Resistance Level | $0.59 | $0.95 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 39.34 | 13.86 |
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.